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Abstract
Background: Few reports are available on the contribution of general and abdominal obesity to the progression of
carotid atherosclerosis in late adulthood. This study investigated the impact of four simple anthropometric
measures of general and abdominal obesity on the progression of carotid atherosclerosis and the extent to which
the association between adiposity and the progression of plaque burden is mediated by cardiometabolic markers.
Methods: Four thousand three hundred forty-five adults (median age 60) from the population-based Tromsø Study
were followed over 7 years from the first carotid ultrasound screening to the next. The progression of carotid
atherosclerosis was measured in three ways: incidence of plaques in previously plaque-free participants; change in the
number of plaques; and total plaque area (TPA). We used generalised linear models to investigate the association
between each adiposity measure – body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and
waist-to-height ratio (WHtR) – and each outcome. Models were adjusted for potential confounders (age, sex, smoking,
education, physical activity). The pathways through which any associations observed might operate were investigated
by further adjusting for cardiometabolic mediators (systolic blood pressure, cholesterol, and HbA1c).
Results: There was little evidence that adiposity was related to the formation of new plaques during follow-up.
However, abdominal adiposity was associated with TPA progression. WHtR showed the largest effect size (mean
change in TPA per one standard deviation (SD) increase in WHtR of 0.665mm2, 95% confidence interval 0.198, 1.133)
while BMI showed the smallest. Effect sizes were substantially reduced after the adjustment for potential mediators.
Conclusions: Abdominal obesity indirectly measured with WC seems more strongly associated with the progression of
TPA than general obesity. These associations appear to be largely mediated by known cardiometabolic markers.
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Background
Obesity is a global epidemic. In 2016, 39% of adults
worldwide were estimated to be overweight, and 13%
obese [1]. The global prevalence of obesity has almost
tripled over the last 30 years and continues to increase
[1]. This trend is of substantial concern, as obesity is as-
sociated with an increase in cardiometabolic disorders
and cardiovascular disease (CVD), the leading cause of
death worldwide. Paradoxically, over this period, the
burden of CVDs has been decreasing in industrialised
countries [2, 3]. However, the current increase in obesity
could offset or reverse the downward trend of CVD
mortality in spite of the decrease in the prevalence of
other traditional CVD risk factors, such as smoking and
hypertension [3]. A recent analysis of US data has sug-
gested that if body mass index (BMI) had not increased,
life expectancy in 2011 at age 40 would be 0.9 years
higher than was actually the case [4], which in part
would be due to a slowdown in the rate of decline of
CVD mortality [5].
Atherosclerosis is a major cause of CVD. Carotid ath-
erosclerosis is easily and non-invasively detected using
ultrasound. Carotid intima-media thickness (IMT) con-
sistently predicts future CVD events, but carotid plaque
outperforms IMT regarding its predictive ability of fu-
ture CVD [6]. Most previous studies on the association
between obesity and carotid atherosclerosis in adults
have been cross-sectional. Relatively few studies have
attempted to look at this relationship prospectively. One
population study investigated the association between
lifetime BMI and IMT in late adulthood and showed
that a reduction in the BMI category was associated with
a decrease in IMT [7]. Several others have investigated
determinants of carotid plaque progression, including
obesity as one of the potential factors [8–11].
If there is evidence of obesity influencing progression,
this is of direct relevance to clinical management in adult-
hood. Also, compared to general obesity (the exposure in
most previous studies), abdominal obesity might play a
more important role in progression because of its stronger
association with cardiometabolic diseases [12].
In an earlier investigation of cross-sectional data from
the population-based Tromsø Study, we have shown that
abdominal obesity was more closely associated with ca-
rotid plaque burden assessed by total plaque area (TPA)
than general obesity [13]. We also found that cardiomet-
abolic risk factors such as hyperlipidemia, glucose in-
tolerance, and hypertension mediated much of this
association. The aim of the current analysis is to extend
these investigations to determine whether the progres-
sion of carotid plaque burden over 7 years is related to
different measures of obesity in the Tromsø Study, and
how far any indication of such an association is medi-
ated by the same set of cardiometabolic risk factors.
Method
Study design and participants
The Tromsø Study [14] is an ongoing population-based
prospective cohort study based on the population of the
municipality of Tromsø in Northern Norway; it consists
of seven surveys spanning 1974–2016 (Tromsø 1–7).
Baseline (1994–95)
The Tromsø Study’s fourth survey (the 4th survey), con-
ducted in 1994–95, is the largest survey to date, inviting
everyone aged 25 years and above living in the Tromsø
municipality. Among the 4th survey’s participants, all
those aged 55–74 years, plus sampling fractions between
5 and 10% from other age groups, were eligible for a sec-
ond visit with extensive clinical examinations including
carotid ultrasound, with 76% (n = 6727) attending [15].
All of the 4th survey’s second visit participants were in-
vited to take part in the 5th (2001) and 6th (2007–08)
surveys for a follow-up ultrasound examination.
Seven-year follow-up at the 5th survey (2001)
All of the 4th survey’s second visit participants, except those
who had died (n= 499) or moved from Tromsø (n= 372),
were invited to the 5th survey’s ultrasound examination (n =
5856), with 83% attending (n= 4858), i.e. 72% of the partici-
pants from the 4th survey’s second visit were rescanned.
After excluding participants without valid written consent
(n= 29) and with missing data on the main covariates (n =
484), 4345 participants were included in the current analysis
of the seven-year follow-up (1994–2001) data.
Fourteen-year follow-up at the 6th survey (2007–08)
All of the 4th survey’s second visit participants, except those
who had died (n= 1515) or moved from Tromsø (n= 468),
were also invited to the 6th survey’s ultrasound examination
(n= 4744), with 63% attending (n= 2975), i.e. 44% of the par-
ticipants from the 4th survey were rescanned. After exclud-
ing those who withdrew their consent (n = 1) or had missing
covariates (n= 289), 2685 participants with complete re-
peated measurements were eligible for the current analysis
of 14-year follow-up (1994–2008) data.
The Regional Committee for Research Ethics and the
Norwegian Data Inspectorate have approved the Tromsø
Study study. All participants included in the present
study have given written informed consent.
Measurement of obesity and other CVD risk factors: the
baseline 4th survey (1994–95)
Height and weight were measured with light clothing and
without shoes using standard methods. Waist circumfer-
ence (WC) was measured at the level of the umbilicus
while hip circumference was measured at the widest part
of the thigh to the nearest 0.5 cm. BMI was calculated by
dividing body weight by height squared. Waist-to-hip ratio
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(WHR) and waist-to-height ratio (WHtR) were calculated
by dividing WC by hip circumference and height, respect-
ively. Categorical adiposity variables were created with
three BMI levels (BMI < 25 kg/m2, 25 < =BMI < 30 kg/m2
(overweight), BMI > =30 kg/m2 (obesity)), two WC levels
(abdominal obesity: men> 102 cm, women> 88 cm), and
two WHR levels (abdominal obesity: men> = 0.9,
women> = 0.85), according to WHO cut-off points [16].
Information on current smoking (yes/no), education level
(primary education, vocational/high school, university/col-
lege), physical activity (hours spent on leisure physical activity
(sweating/out of breath) per week in leisure time: none, less
than one, one to two, three or more), and medical history
(myocardial infarction, angina pectoris, stroke, diabetes) was
obtained by self-administered questionnaires. Non-fasting
serum total cholesterol, triglycerides, and high-density lipo-
protein cholesterol (HDL-C) were determined using standar-
dised methods. Low-density lipoprotein cholesterol (LDL-C)
was calculated using the Friedewald equation. HbA1c was
measured using the Cobas Mira instrument. Blood pressure
was measured seated three times with a one-minute interval
between readings after one minute of seated rest, using an
automatic device (Dinamap Vital Signs Monitor 1846; Criti-
kon Inc., Tampa, FL, USA). The average of the last two
blood pressure measurements was used in the analysis.
Ultrasound examination: the 4th, 5th, and 6th surveys
(1994–2008)
The right carotid artery was scanned in the far and near wall
of the common carotid artery, bifurcation, and internal ca-
rotid artery to seek for carotid plaques using an Acuson Xp
10,128 ART ultrasound scanner equipped with a 7.5MHz
linear-array transducer in the 4th and 5th surveys, and a GE
Vivid 7 scanner with a linear 12MHz transducer in the 6th
survey, as previously described [17, 18]. The same protocol
was used in all surveys. Carotid plaque was defined as a focal
structure encroaching into the arterial lumen at least 0.5mm
or 50% of the surrounding IMT value or IMT > 1.5mm as
measured from the media-adventitia interface to the intima-
lumen interface. Cine loops and still images of each carotid
plaque in the longitudinal plane were stored and digitalised
for offline analysis. All plaque images were outlined manually
to assess plaque areas using the Adobe Photoshop imaging-
procession programme (ver. 7.0.1). When there were mul-
tiple plaques, all plaque areas were summarised to calculate
TPA. Inter-equipment variability and intra-reader and inter-
reader reproducibility of plaque detection and measurement
of plaque area were acceptable [17, 18].
Statistical analysis
Primary analysis: changes from the baseline 4th survey to
the 5th survey (1994–2001)
Baseline characteristics were summarised as means with
standard deviations (SD) (or medians with the inter-
quartile range if markedly non-normally distributed) for
continuous variables, and counts and frequencies (per-
centages) for categorical variables.
We used three outcomes to assess the progression of
carotid atherosclerosis: new plaque formation (binary
yes/no) in those without plaque at baseline; change in
the number of plaques from baseline to follow-up; and
change in TPA over the same period.
To directly compare the strength of association of each
adiposity measure, taking account of the different distri-
butions in men and women, we calculated sex-specific
standardised adiposity scores by subtracting the sex-
specific mean of each adiposity measure from the ob-
served value and then dividing by the sex-specific SD.
The association between new plaque formation and each
adiposity measure was examined using a series of logistic
regression models. The effect of each adiposity measure
on the change in the number of plaques/TPA was esti-
mated using analogous linear regression models. Due to
concerns over the normality assumption, we also con-
structed confidence intervals (CIs) using a bootstrap ap-
proach, as described in the Appendix. Separately for
each outcome variable and each adiposity measure, we
fitted a sequence of three models. We selected potential
confounders and mediators a priori based on evidence of
the association between obesity and CVD. Model 1 was
adjusted for age (categorical five-year interval) and sex.
Model 2 was further adjusted for the other potential be-
havioural and socio-demographic confounders (smoking,
physical activity, education), this being our main model
for estimating the association between adiposity and the
progression of atherosclerosis. To assess the extent to
which any observed associations in model 2 might be
mediated by cardiometabolic risk factors, model 3 was
further adjusted for the following potential mediators:
systolic blood pressure, HDL-C, LDL-C, and glycated
haemoglobin as continuous variables, and antihyperten-
sive- and lipid-lowering drug use and existing diabetes
as binary variables.
STATA version 14 (StataCorp) was used for all analyses.
Secondary analyses: changes from the baseline 4th survey
to the 6th survey (1994–2008)
We conducted parallel analyses to those above using the
6th survey follow-up data (2008). In planning this study,
we had intended to focus equally on this analysis. How-
ever, having undertaken the analysis, the sample size was
appreciably smaller after the 14-year follow-up, and effect
estimates markedly less precise than those from our 5th
survey analysis. Therefore, we focus our presentation on
the 5th survey analysis. As our initial intention was to in-
clude analyses from the 6th survey data and to avoid pub-
lication bias, analyses involving the 6th survey after the
Imahori et al. BMC Cardiovascular Disorders          (2020) 20:138 Page 3 of 10
Table 1 Participant characteristics at baseline (Tromsø Study the 4th survey: analysis restricted to participants with all covariates and
outcomes at both 4th and 5th survey: n = 4345)
Total (4345) Men (2114) Women (2231)
Age (years) median (IQR) 60 (55–66) 60 (55–65) 61 (56–67)
Anthropometric measures Mean ± SD
Height (cm) 168.5 ± 9.4 175.6 ± 6.7 161.8 ± 6.2
Weight (kg) 74.0 ± 13.0 80.6 ± 11.5 67.8 ± 11.2
BMI (kg/m2) 26.0 ± 3.7 26.1 ± 3.2 25.9 ± 4.2
WC (cm) 89.7 ± 11.0 95.0 ± 9.0 84.7 ± 10.5
WHR 0.87 ± 0.08 0.92 ± 0.06 0.82 ± 0.06
WHtR 0.53 ± 0.06 0.54 ± 0.05 0.52 ± 0.07
Categorical obesitya N(%)
BMI < 25 kg/m2 1836 (42.3) 803 (38.0) 1033 (46.3)
25 < =BMI < 30 kg/m2 (Overweight) 1930 (44.4) 1087 (51.4) 843 (37.8)
BMI > =30 kg/m2(Obesity) 579 (13.3) 224 (10.6) 355 (15.9)
WC: m > 102 cm, w > 88 cm (Abdominal obesity) 1226 (28.2) 449 (21.2) 777 (34.8)
WHR m > =0.9 f > =0.85(Abdominal obesity) 1850 (42.6) 1245 (58.9) 605 (27.1)
Potential confounders N(%)
Current Smoker 1290 (29.7) 657 (31.1) 633 (28.4)
Physical activity (hours/week) b
None 2666 (61.4) 1077 (51.0) 1589 (71.2)
Less than 1 673 (15.5) 381 (18.0) 292 (13.1)
1–2 670 (15.4) 421 (19.9) 249 (11.2)
3 or more 336 (7.7) 235 (11.1) 101 (4.5)
Education
Primary education 2229 (51.3) 910 (43.1) 1319 (59.1)
Vocational/high school 1328 (30.6) 738 (34.9) 590 (26.5)
University/college 788 (18.1) 466 (22.0) 322 (14.4)
Potential mediators Mean ± SD
Systolic blood pressure (mmHg) 143.4 ± 21.5 143.6 ± 19.4 143.2 ± 23.2
Total cholesterol (mmol/l) 6.69 ± 1.27 6.51 ± 1.18 6.85 ± 1.32
Triglycerides (mmol/l) 1.51 ± 0.88 1.62 ± 0.96 1.41 ± 0.79
HDL cholesterol (mmol/l) 1.52 ± 0.44 1.37 ± 0.39 1.66 ± 0.44
LDL cholesterol (mmol/l) 4.48 ± 1.17 4.40 ± 1.09 4.55 ± 1.22
HbA1c (%) 5.44 ± 0.63 5.42 ± 0.57 5.47 ± 0.68
Medical history/Medication N(%)
Myocardial infarction 197 (4.5) 156 (7.4) 41 (1.8)
Angina pectoris 335 (7.7) 198 (9.4) 137 (6.1)
Stroke 83 (1.9) 42 (2.0) 41 (1.8)
Diabetes 96 (2.2) 46 (2.2) 50 (2.2)
Lipid-lowering drug use 114 (2.6) 64 (3.0) 50 (2.2)
Blood pressure lowering drug use 515 (11.9) 248 (11.7) 267 (12.0)
TPA at T4 (IQR)
TPA Q1 0–0 0–0 0–0
TPA Q2 0–0 0–4.0 0–0
TPA Q3 0–12.9 4.0–16.2 0–10.4
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14-year follow-up are reported only in supplementary ta-
bles, although the results were largely uninformative.
Results
Baseline characteristics
Table 1 shows participant characteristics at baseline.
The median age of participants was 60 years (interquar-
tile range 55–66), and 51% were women. Compared to
the 4th survey’s second visit participants who did not at-
tend the 5th or 6th surveys, the attending population
was younger and with a more favourable CVD risk pro-
file (Tables S1–S2). Adiposity measures were approxi-
mately normally distributed. According to the BMI
classification, 44.4 and 13.4% of the participants were
categorised as overweight and obesity, respectively. In-
creased WC (men> 102 cm, women> 88 cm) was ob-
served in 28.3% of the participants while 42.7% had
increased WHR (men> = 0.9, women> = 0.85). Lipid-
lowering drug use prevalence was 2.6%.
At baseline, 46.2% of participants had at least one
plaque. The median TPA in subjects with plaques was
15.7 mm2 in men and 12.7 mm2 in women.
Carotid plaque burden at seven-year follow-up
Table 2 shows carotid plaque burden at the 5th survey
by category of adiposity 7 years earlier at the 4th survey.
At the seven-year follow-up, 62.2% of the participants
had at least one plaque. Among the 2337 participants
without plaque at the baseline 4th survey, 40% developed
at least one new plaque. Median TPA increased from 0
mm2 at baseline to 8.9 mm2. Participants who belong to
a higher adiposity category were more likely to have a
higher plaque burden and greater progression of plaque
burden compared to those in lower categories.
New plaque formation among participants without
plaque at baseline (baseline – the 5th survey)
Table 3 shows odds ratios for developing at least one
plaque at the seven-year follow up among the 2337 par-
ticipants without plaque at baseline per 1 SD increase in
each adiposity index. After adjustment for confounders
only, all estimated odds ratios were small and non-
significant.
Progression of plaque number (baseline – the 5th survey)
Table 4 shows the estimated changes in the number of
plaques per 1 SD increase in each adiposity measure at
baseline. After adjustment for confounders (model 2), no
adiposity measure except for WHR was significantly as-
sociated with changes in the number of plaques.
Progression of TPA (baseline – the 5th survey)
Table 4 shows the estimated changes in TPA per 1 SD in-
crease in each adiposity measure at baseline. After adjust-
ment for confounders (model 2), there were statistically
significant associations between the progression in TPA
and all adiposity measures except for BMI. WHtR showed
the largest regression coefficient, followed by WHR, and
BMI showed the smallest. After further adjustment for po-
tential mediators (model 3), all effect sizes decreased sub-
stantially, and all became non-significant.
Fourteen-year follow-up (baseline - the 6th survey)
Analogous tables to those above for the 6th survey
follow-up data are shown in Tables S3–5. These analyses
included markedly fewer people than those for the 5th
survey follow-up, and effect estimates were consequently
considerably less precise with wide CIs.
Table 1 Participant characteristics at baseline (Tromsø Study the 4th survey: analysis restricted to participants with all covariates and
outcomes at both 4th and 5th survey: n = 4345) (Continued)
Total (4345) Men (2114) Women (2231)
TPA Q4 12.9–135.1 16.2–135.1 10.4–121.2
Number of plaques at T4 N (%)
0 2337 (53.8) 1027 (48.6) 1310 (58.7)
1 1268 (29.2) 655 (31.0) 613 (27.5)
2 534 (12.3) 295 (14.0) 239 (10.7)
3 147 (3.4) 95 (4.5) 52 (2.3)
4 49 (1.1) 35 (1.7) 14 (0.6)
5 9 (0.2) 7 (0.3) 2 (0.1)
6 1 (0.02) 1 (0.04)
BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, HDL high-density lipoprotein, LDL low-density lipoprotein,
HbA1c glycated haemoglobin, TPA total plaque area
aIncreased waist circumference (> 102 cm for men, > 88 cm for women) and increased WHR (> = 0.9 for men, > = 0.85 for women) are categorised according to
WHO cut-off points [1]. bHours spent on hard physical activity (sweating/out of breath) in leisure time
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Discussion
In this seven-year follow-up of a population-based sample of
women and men in late adulthood, we found that abdominal
obesity was more strongly associated with the progression of
carotid plaque burden than general obesity. New plaque for-
mation among participants without plaque at baseline was,
however, not associated with any adiposity measures. Fur-
thermore, all significant associations observed were in part
mediated by cardiometabolic risk factors.
Our results suggest that abdominal obesity in late
adulthood might contribute to the progression of carotid
plaque burden with larger effect estimates than general
obesity, imposing an excess risk on the progression of
atherosclerosis. This finding concurs with our previous
findings from a cross-sectional analysis, although consid-
erable overlap of CIs prevents us from drawing definitive
conclusions [13].
Several previous studies have investigated the effect of
general obesity on the progression of carotid atherosclerosis
[8–10]. Herder et al. investigated the determinants of the
progression of IMT and TPA after a 13-year follow-up; in
this study, BMI at baseline did not predict progression of
either [8]. Similarly, van der Meer et al. showed that BMI
was not associated with an increase in plaque numbers over
an average follow-up of 6.5 years [9]. Molino-Lova et al.
showed that overweight/obesity, according to BMI cat-
egory, was not associated with the new formation of plaque
in 486 elderly participants without plaque at baseline over a
three-year follow-up period [10]. All of these findings agree
with the relatively weak association between BMI and the
progression of atherosclerosis in our analysis.
On the other hand, not much has been done to clarify
the influence of abdominal obesity on the progression of
carotid atherosclerosis. One prospective study (n = 1894)
with a four-year follow-up showed that an increase in
WC was one of the determinants of the new formation
of plaque among 462 participants without plaque at
baseline after adjustment for age, sex, and follow-up
time, while BMI was not [11]. However, neither was a
determinant of the progression of TPA. In the Rotter-
dam Study, the determinants of the progression of the
number of plaques were analysed in 3409 participants
after the 6.5-year follow-up. An increase in WHR was
associated with an increase in the number of plaques
after adjustment for traditional CVD risk factors. Again,
BMI was not associated with increases in the number of
plaques [9]. Although a direct comparison of their find-
ings with ours is difficult due to differences in statistical
Table 2 Carotid plaque at the 5th survey (2001) according to adiposity category at the baseline 4th survey (1994–95) (n = 4345)
Total
population
BMI categories WC categoriesa WHR categoriesa
Carotid variable n/N (%) BMI < 25 kg/
m2 n/N (%)
25 < =BMI <
30 kg/m2
(Overweight)
n/N (%)
BMI > =30
kg/m2
(Obesity)
n/N (%)
Abdominal obesity Abdominal obesity
No n/N (%) Yes n/N (%) No n/N (%) Yes n/N (%)
At least one plaque at T5 2704/4345
(62.2)
1078/1836
(58.7)
1250/1930
(64.8)
376/579
(64.9)
1901/3119
(61.0)
803/1226
(65.5)
1414/2495
(56.7)
1290/1850
(69.7)
New plaques at T5b 938/2337
(40.1)
374/1021
(36.6)
450/1028
(43.8)
114/288
(39.6)
660/1703
(38.8)
278/634
(43.9)
521/1454
(35.8)
417/883
(47.2)
Number of plaques at T5
0 1641 (37.8) 758 (41.3) 680 (35.2) 203 (35.1) 1218 (39.1) 423 (34.5) 1081 (43.3) 560 (30.3)
1 1230 (28.3) 478 (26.0) 578 (30.0) 174 (30.1) 861 (27.6) 369 (30.1) 675 (27.1) 555 (30.0)
2 869 (20.0) 361 (19.7) 378 (19.6) 130 (22.5) 614 (19.7) 255 (20.8) 463 (18.6) 406 (22.0)
+ 3 605 (13.9) 239 (13.0) 294 (15.2) 72 (12.4) 426 (13.7) 179 (14.6) 276 (11.1) 329 (17.8)
Change in number of plaques from T4 to T5
Decreased 442 (10.2) 181 (9.9) 198 (10.3) 63 (10.9) 304 (9.8) 138 (11.3) 243 (9.7) 199 (10.8)
No change 2191 (50.4) 960 (52.3) 943 (48.9) 288 (49.7) 1612 (51.7) 579 (47.2) 1349 (54.1) 842 (45.5)
Increased 1712 (39.4) 695 (37.9) 789 (40.9) 228 (39.4) 1203 (38.6) 509 (41.5) 903 (36.2) 809 (43.7)
Median (IQR)
TPA at T5 (mm2) 8.9 (1–22.6) 7.5 (0–20.7) 9.7 (0–24.6) 10.9 (0–
24.3)
8.3 (0–21.7) 10.4 (0–
24.4)
6.6 (0–18.8) 12.5 (0–28.8)
Change in TPA from T4 to
T5 (mm2)
0 (0–12.1) 0 (0–10.6) 1.6 (0–13.1) 0.7 (0–12.1) 0 (0–11.5) 1.7 (0–13.5) 0 (0–9.3) 3.7 (0–15.2)
Data are count and percentage for binary plaque and median and IQR for number of plaques and TPA. BMI: body mass index, T4: Tromsø Study the fourth survey,
T5: Tromsø Study the fifth survey, TPA: total plaque area
WC: waist circumference, WHR: waist-to-hip ratio, WHtR: waist-to-height ratio, TPA: total plaque area
aAbdominal obesity WC: > 102 cm for men, > 88 cm for women, WHR: > = 0.9 for men, > = 0.85 for women (categorised according to WHO cut-off points, b New
plaques at T5: The number of participants who developed at least one plaque among participants without plaque at T4
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methods and adjustments, the potentially stronger effect
of abdominal obesity compared to general obesity is
consistent with our results.
The objectives of the studies mentioned above were to
investigate the determinants of the progression of ath-
erosclerosis [8, 9, 11] or the association between main
exposures other than obesity and atherosclerosis [10].
When restricted to studies directly investigating the as-
sociation between obesity and atherosclerosis, there is
some evidence that IMT in adulthood may partly reflect
childhood obesity [19–24]. However, the question of
whether or not the development or progression of ca-
rotid plaque in adult life is related to obesity in early life
has not been investigated.
Most previous studies have used BMI to assess obesity.
However, BMI does not provide information about fat distri-
bution. Abdominal obesity, reflecting excess visceral adipose
tissue, has a stronger association with inbsulin resistance and
dyslipidemia than general obesity [12]. Regarding whether ab-
dominal obesity is more strongly associated with CVD than
general obesity, evidence from observational studies is incon-
sistent. The Emerging Risk Factors Collaboration analysed
221,934 individuals from 58 cohorts and found that BMI,
WC, andWHR were all associated with CVD risk, and the au-
thors concluded that their effect sizes were similar [25].
On the other hand, some studies suggest a stronger ef-
fect of abdominal obesity than general obesity. The
INTERHEART Study, a large multi-centre case-control
study with 12,461 myocardial infarction cases, suggested
that increased WHR was more strongly associated with
the occurrence of myocardial infarction than BMI [26].
Furthermore, the recent INTERSTROKE Study showed
that WHR had a stronger association with stroke than
BMI had [27].
Recently, two large Mendelian randomisation studies
have shed light on the effect of abdominal obesity on
CVD [28, 29]. Dale et al. analysed data from 14 pro-
spective studies with 66,842 coronary heart disease cases
and 12,389 ischemic stroke cases, and compared associa-
tions of genetic risk scores for BMI and WHR adjusted
for BMI with various cardiometabolic risks. The results
showed that WHR might have a stronger effect on cor-
onary heart disease and stroke than BMI. In particular,
only WHR was associated with increased risk of ische-
mic stroke [29]. Another study, with 111,986 partici-
pants from the UK Biobank, showed that a genetic
Table 3 Odds ratios of having plaques at the 5th survey (2001) among participants without plaques at the baseline 4th survey
(1994–95), by adiposity at the 4th survey (incident plaque when plaque is absent at the 4th survey) (n = 2337)
Model 1 OR (95%CI) p-value Model 2 OR (95%CI) p-value Model 3 OR (95%CI) p-value
BMI (per 1 SD) 0.98 (0.89, 1.08) 0.75 1.03 (0.93, 1.13) 0.60 0.94 (0.85, 1.05) 0.29
WC (per 1 SD) 1.01 (0.92, 1.11) 0.87 1.04 (0.94, 1.15) 0.44 0.96 (0.86, 1.07) 0.49
WHR (per 1 SD) 1.06 (0.96, 1.16) 0.24 1.06 (0.97, 1.17) 0.20 1.01 (0.92, 1.12) 0.77
WHtR (per 1 SD) 1.04 (0.94, 1.14) 0.49 1.07 (0.96, 1.18) 0.21 0.98 (0.87, 1.09) 0.68
BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, OR odds ratio, 95% CI 95% confidence interval, SD standard
deviation, Model 1: adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3:
adjusted for variables in Model 2 and mediators (systolic blood pressure, HDL cholesterol, LDL cholesterol, glycated haemoglobin, diabetes, lipid and blood
pressure-lowering drug)
Table 4 Changes in the number of plaques and total plaque area between the baseline 4th survey (1994–95) and the 5th survey
(2001) per 1 SD increase in baseline adiposity (number of plaques: n = 4345, total plaque area: n = 4302)
Number of plaques
Model 1 β (95%CI) p-value Model 2 β (95%CI) p-value Model 3 β (95%CI) p-value
BMI (per 1 SD) −0.016 (−0.047, 0.015) 0.32 0.004 (− 0.028, 0.035) 0.82 − 0.011 (− 0.046, 0.023) 0.51
WC (per 1SD) 0.001 (− 0.030, 0.032) 0.97 0.014 (− 0.017, 0.045) 0.38 0.002 (− 0.031, 0.036) 0.89
WHR (per 1 SD) 0.029 (−0.002, 0.060) 0.07 0.032 (0.001, 0.064) 0.04 0.028 (−0.005, 0.061) 0.09
WHtR (per 1 SD) 0.010 (−0.021, 0.042) 0.52 0.024 (−0.008, 0.056) 0.14 0.013 (−0.021, 0.048) 0.45
Total plaque area
BMI (per 1 SD) 0.184 (−0.298, 0.666) 0.45 0.412 (−0.077, 0.902) 0.10 0.005 (−0.525, 0.534) 0.99
WC (per 1 SD) 0.468 (−0.014, 0.949) 0.06 0.608 (0.122, 1.094) 0.01 0.261 (−0.260, 0.782) 0.33
WHR (per 1 SD) 0.698 (0.211, 1.185) 0.005 0.697 (0.209, 1.186) 0.005 0.471 (−0.038, 0.980) 0.07
WHtR (per 1 SD) 0.614 (0.122, 1.106) 0.01 0.750 (0.252, 1.249) 0.003 0.397 (−0.138, 0.932) 0.15
BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, OR odds ratio, 95% CI 95% confidence interval, SD standard
deviation, Model 1: adjusted for age and sex, Model 2: adjust for variables in Model 1 plus other confounders (smoking, physical activity and education), Model 3:
adjusted for variables in Model 2 and mediators (systolic blood pressure, HDL cholesterol, non-HDL cholesterol, glycated haemoglobin, diabetes, lipid and blood
pressure-lowering drug)
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disposition to higher WHR adjusted for BMI was associ-
ated with type 2 diabetes and coronary heart disease,
supporting causal relationships [28]. These findings em-
phasise the important role of abdominal obesity. Using
BMI may lead to underestimation of the true risk of
obesity for CVD.
In the present study, associations were more statistically
significant in the analyses using TPA as an outcome than
those using the number of plaques. It is expected that
continuous plaque variables such as TPA and total plaque
volume (TPV) can capture the small change in plaque
over time more easily than a simple categorical plaque
variable, requiring smaller sample sizes and potentially
shorter follow-up time to detect significant changes. It has
also been suggested that TPA is likely to be more sensitive
to the progression of atherosclerosis than the more com-
monly studied outcome of IMT because plaque grows
along the axis of the artery 2.4 times faster than it changes
in thickness [30]. One study, with 349 atherosclerotic pa-
tients, compared the predictive ability of future CVD
events among TPV, TPA, and IMT after a five-year
follow-up [31]. Progression of TPV was significantly asso-
ciated with CVD events after the adjustment for trad-
itional CVD risk factors. Although the predictive ability of
TPA was inferior to TPV, TPA performed better than
IMT. While TPV is more sensitive to the progression with
its three-dimensional information, TPA would be sensitive
enough to detect the progression of plaque burden within
a reasonable time frame, which makes TPA an attractive
outcome in large population-based studies.
New plaque formation was not associated with any
adiposity measures. Considering that our sample was in
late adulthood, having no plaque at baseline might mean
that participants are to some extent resistant to athero-
sclerotic changes for genetic or other reasons. This
might contribute to the slower progression of carotid
atherosclerosis and make it difficult to detect changes in
this population. Another potential explanation is lack of
power: by restricting the analysis to participants without
plaque at baseline, the sample size was almost halved.
Besides, like the number of plaques variable, the binary
plaque variable provides less statistical information on
the progression of plaque burden than a continuous
plaque variable capturing size such as TPA.
All effect sizes of observed associations between obesity
and the progression of plaque burden in the main analysis
were substantially reduced after the adjustment for cardio-
metabolic risk factors in model 3, and no associations
remained significant. This finding is supported by previous
studies where strong determinants of the progression of
carotid plaque burden included systolic blood pressure
and total cholesterol [8, 9]. Our finding validates that the
pathway from obesity to carotid atherosclerosis is at least
in part through cardiometabolic risk factors.
Recent studies with CVD mortality as an outcome also
showed that the risk of obesity for atherosclerotic CVD
is largely or fully mediated by these cardiometabolic risk
factors [32, 33]. These findings suggest that the strict
control of metabolic risk factors might in part attenuate
the risk of obesity on the progression of atherosclerosis.
Interventions to bring long-term and sustained weight
loss through lifestyle change have not been uniformly
successful [34, 35]. On the other hand, the effective
treatment of cardiometabolic risk factors is established,
and with strict control of this might reduce the indirect
effect of obesity on atherosclerosis. Nevertheless, the
treatment of obesity is vital to block any direct pathway to
the progression of atherosclerosis and to control cardiomet-
abolic risk factors better [36]. Because our main objective
was to investigate the association between obesity and
plaque burden with and without the adjustment for media-
tors as a whole, this did not require partitioning of the con-
tribution of a specific mediator to the overall effect.
Our major strength is a large sample size with a rela-
tively long follow-up period, which allowed us a reason-
able estimation of the association between the
progression of carotid atherosclerosis and obesity. Fur-
thermore, theTromsø Study is one of the few prospect-
ive studies with repeated carotid plaque measurements.
The use of the quantitative plaque variable TPA is an-
other advantage.
Our main limitation is a loss to follow-up. This might
reduce the power of the study to detect associations be-
tween adiposity and the progression of carotid plaque
burden. In addition, selection bias may be introduced.
Thus, the association should be interpreted with caution,
as should generalisability to the whole population. An-
other limitation is the possibility of residual confound-
ing. For example, we did not include statin use in the
model because statin use was not common at baseline.
With respect to smoking, we only had data on this as a
binary variable (current smoker: yes/no), which may
have resulted in some residual confounding, as it is
known that former smokers have a higher CVD risk
than non-smokers [37].
Furthermore, we did not consider subsequent changes in
CVD risk factors and medications. Moreover, the abdom-
inal obesity index that we used is a crude measure of ab-
dominal adipose tissue. However, it is easily available in a
real-world clinical setting. Further study using the reliable
measurement of visceral adipose tissue and body compos-
ition overall would be informative. Several studies have
shown that a decrease in lean mass or skeletal muscle mass
was associated with CVD and atherosclerosis [38–40]. In
terms of WC, we measured WC at the level of the umbil-
icus, which tends to give higher WC values compared to
other WC measurement sites [41]. However, a systematic
literature review concluded that the WC measurement site
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had little impact on the association of WC with CVD mor-
tality, CVD events, or risk of diabetes [42]. Finally, only the
right carotid artery was assessed.
Conclusion
Abdominal obesity, especially WHtR and WHR, seems
to be more strongly associated with the progression of
carotid atherosclerosis than general obesity. These asso-
ciations are largely mediated by established cardiometa-
bolic risk factors.
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